BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QLS4131 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QLS4131\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07001839-3368@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:QLS4131: Phase 1 readout est. (NCT07001839)
DESCRIPTION:QLS4131\, phase 1.\nStudy: A Phase Ib Study of QLS4131 in Subje
 cts With Systemic Lupus Erythematosus\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qls4131#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0700183
 9
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903636-3368@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:QLS4131: Phase 2 readout est. (NCT07903636)
DESCRIPTION:QLS4131\, phase 2\, Multiple Myeloma.\nStudy: QLS4131 for Relap
 sed/Refractory Multiple Myeloma With Extramedullary Disease\nEstimated pri
 mary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/qls4131#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07903636
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07921615-3368@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20271209
DTEND;VALUE=DATE:20271210
SUMMARY:QLS4131: Phase 2 readout est. (NCT07921615)
DESCRIPTION:QLS4131\, phase 2.\nStudy: QLS4131 Plus Isa-V-CHOP in Newly Dia
 gnosed\, HIV-Negative PBL: A Single-Center\, Single-Arm\, Phase II Study\n
 Estimated primary completion: 9 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/qls4131#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07921615
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751471-3368@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLS4131: Phase 2 readout est. (NCT07751471)
DESCRIPTION:QLS4131\, phase 2.\nStudy: BCMA/GPRC5D Trispecific Antibody Tre
 atment for Newly Diagnosed Amyloidosis (AL-004)\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/qls4131#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07751471
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560449-3368@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:QLS4131: Phase 2 readout est. (NCT07560449)
DESCRIPTION:QLS4131\, phase 2.\nStudy: QLS4131 Combination Therapy in Malig
 nant Plasma Cell Neoplasms\nEstimated primary completion: June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/qls4131#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07560449
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933432-3368@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20291214
DTEND;VALUE=DATE:20291215
SUMMARY:QLS4131: Phase 3 readout est. (NCT07933432)
DESCRIPTION:QLS4131\, phase 3\, Multiple Myeloma.\nStudy: A Study in Partic
 ipants With Relapsed or Refractory Multiple Myeloma for QLS4131\nEstimated
  primary completion: 14 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/qls4131#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07933432
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903623-3368@assetmemo.bio
DTSTAMP:20261121T005823Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:QLS4131: Phase 2 readout est. (NCT07903623)
DESCRIPTION:QLS4131\, phase 2.\nStudy: QLS4131 Plus Isatuximab in Newly Dia
 gnosed Primary Plasma Cell Leukemia\nEstimated primary completion: 30 Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qls4131#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079036
 23
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
